FIRST REPORT OF THE PHASE-I STUDY OF THE NOVEL ORAL JAK2 INHIBITOR SB1518 IN PATIENTS WITH MYELOFIBROSIS

被引：0
|
作者：
Seymour, F. [1 ]
To, B. [2 ]
Goh, A. [3 ]
Meadows, L. [1 ]
Ethirajulu, A. [3 ]
Wood, A. [3 ]
Zhu, A. [4 ]
Roberts, W. [5 ]
机构：
[1] Peter MacCallum Canc Ctr, Melbourne, Australia
[2] Royal Adelaide Hosp, Inst Med & Vet Sci, Adelaide, SA 5000, Australia
[3] S BIO Pty Ltd, Singapore, Singapore
[4] S BIO Pty Ltd, Redwood City, CA USA
[5] Royal Melbourne Hosp, Parkville, Vic 3050, Australia
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1144
引用
收藏
页码：472 / 472
页数：1
相关论文
共 50 条
  • [21] Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia Polycythemia Vera Myelofibrosis
    Verstovsek, Srdan
    Odenike, Olatoyosi
    Scott, Bart
    Estrov, Zeev
    Cortes, Jorge
    Thomas, Deborah A.
    Wood, Jeanette
    Ethirajulu, Kantharaj
    Lowe, Ann
    Zhu, Huan J.
    Kantarjian, Hagop
    Deeg, H. Joachim
    BLOOD, 2009, 114 (22) : 1502 - 1502
  • [22] Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis
    Vaddi, Kris
    Sarlis, Nicholas J.
    Gupta, Vikas
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (16) : 2397 - 2407
  • [23] Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis
    Mascarenhas, John
    Baer, Maria R.
    Kessler, Craig
    Hexner, Elizabeth
    Tremblay, Douglas
    Price, Leah
    Sandy, Lonette
    Weinberg, Rona
    Pahl, Heike
    Silverman, Lewis R.
    Goldberg, Judith D.
    Kosiorek, Heidi
    Dueck, Amylou C.
    Hoffman, Ronald
    LEUKEMIA & LYMPHOMA, 2019, 60 (05) : 1343 - 1345
  • [24] Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis
    Pardanani, Animesh
    Gotlib, Jason
    Gupta, Vikas
    Roberts, Andrew W.
    Wadleigh, Martha
    Sirhan, Shireen
    Bavisotto, Linda M.
    Kawashima, Jun
    Kowalski, Mark
    Tefferi, Ayalew
    BLOOD, 2012, 120 (21)
  • [25] Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes (vol 30, pg 4161, 2012)
    Younes
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (30) : 3461 - 3461
  • [26] A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis
    Verstovsek, Srdan
    Hoffman, Ronald
    Mascarenhas, John
    Soria, Jean-Charles
    Bahleda, Ratislav
    McCoon, Patricia
    Tang, Weifeng
    Cortes, Jorge
    Kantarjian, Hagop
    Ribrag, Vincent
    LEUKEMIA RESEARCH, 2015, 39 (02) : 157 - 163
  • [27] AZD1480: A Phase I Study of a Novel JAK2 Inhibitor in Solid Tumors
    Plimack, Elizabeth R.
    LoRusso, Patricia M.
    McCoon, Patricia
    Tang, Weifeng
    Krebs, Annetta D.
    Curt, Gregory
    Eckhardt, S. Gail
    ONCOLOGIST, 2013, 18 (07): : 819 - 820
  • [28] Oral Decitabine/Cedazuridine Is an Effective Ambulatory Therapy for Patients With Myelofibrosis Refractory to JAK2 Inhibitor Therapy
    Handa, Shivani
    Sivakumar, Ganesh
    Srisuwananukorn, Andrew
    Dueck, Amylou
    Tremblay, Douglas
    Mascarenhas, John
    Ginzburg, Yelena
    Kremyanskaya, Marina
    Hoffman, Ronald
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (09): : e314 - e319
  • [29] A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis
    S Verstovsek
    M Talpaz
    E Ritchie
    M Wadleigh
    O Odenike
    C Jamieson
    B Stein
    T Uno
    R A Mesa
    Leukemia, 2017, 31 : 393 - 402
  • [30] A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis
    Verstovsek, S.
    Talpaz, M.
    Ritchie, E.
    Wadleigh, M.
    Odenike, O.
    Jamieson, C.
    Stein, B.
    Uno, T.
    Mesa, R. A.
    LEUKEMIA, 2017, 31 (02) : 393 - 402
12345